ArticleMethods in molecular biology (Clifton, N.J.)2026
A PD-1/PD-L1-Sensitive Co-culture-Based Primary T-Cell Activation Assay.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death protein 1 (PD-1) is crucial in inhibiting immune responses by modulating the activity of T cells. We present an in vitro assay that is based on a co-culture of primary immune cells represented by human peripheral blood mononuclear cells (PBMCs), isolated from healthy donors with Chinese hamster ovary-derived cell line (CHO-K1) overexpressing human PD-L1 protein (hPD-L1) and an artificial TCR-activator construct (TCRAct). CHO-K1/TCRAct/hPD-L1 cells mimic antigen-presenting cells by activating T cells via the T-cell receptor (TCR) and providing a ligand for the negative immune checkpoint (PD-L1 protein). The two components, PBMCs and CHO-K1/TCRAct/hPD-L1 cells, when in co-culture, provide a T-cell activation (TCA) assay, which may be used to test the potency of molecules targeting the PD-1/PD-L1 immune checkpoint. This method relies on monitoring the activation of helper CD4+ and cytotoxic CD8+ T cells using flow cytometry by analyzing the expression levels of early (CD69), intermediate (CD25 and HLA-DR), and late (PD-1) activation/exhaustion markers. This is the well-established in vitro co-culture assay in which primary T-cell activation via the TCR is diminished by the concurrent presence of PD-1/PD-L1 immune checkpoint, which can be blocked resulting in increased expression of T-cell surface markers.
Indexed as
Identifiers
41028260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.